- AMED has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $11.1 million.
- AMED has traded 80,335 shares today.
- AMED is trading at 11.09 times the normal volume for the stock at this time of day.
- AMED is trading at a new high 6.06% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in AMED with the Ticky from Trade-Ideas. See the FREE profile for AMED NOW at Trade-Ideas More details on AMED:
Amedisys, Inc., together with its subsidiaries, provides home health and hospice care services. It operates through two segments, Home Health and Hospice. The Home Health segment offers a range of services in the homes of individuals who may be recovering from illness, injury, or surgery. Currently there is 1 analyst that rates Amedisys a buy, 1 analyst rates it a sell, and 7 rate it a hold.The average volume for Amedisys has been 209,400 shares per day over the past 30 days. Amedisys has a market cap of $1.1 billion and is part of the health care sector and health services industry. The stock has a beta of 0.42 and a short float of 4.4% with 3.05 days to cover. Shares are up 16.3% year-to-date as of the close of trading on Monday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Amedisys as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and good cash flow from operations. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Highlights from the ratings report include:
- Compared to its closing price of one year ago, AMED's share price has jumped by 139.91%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
- AMED's revenue growth trails the industry average of 13.2%. Since the same quarter one year prior, revenues slightly increased by 0.9%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- AMED's debt-to-equity ratio is very low at 0.27 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Despite the fact that AMED's debt-to-equity ratio is low, the quick ratio, which is currently 0.69, displays a potential problem in covering short-term cash needs.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Health Care Providers & Services industry and the overall market, AMEDISYS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Providers & Services industry. The net income has significantly decreased by 181.9% when compared to the same quarter one year ago, falling from -$12.42 million to -$35.01 million.
- You can view the full Amedisys Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.